FDA Approves Mirikizumab (Omvoh) for Ulcerative Colitis; Eli Lilly and Company announced the FDA approval of mirikizumab (Omvoh) for moderately and severely active ulcerative colitis in adults on October 26, 2023.

Media coverage

• Title	FDA Approves Mirikizumab for Moderately to Severely Active Ulcerative Colitis
  Media name/outlet	Pharmacy Times
  Country/Territory	United States
  Date	27/10/23
  URL	ct.moreover.com/?a=52174600690&p=1gw&v=1&x=16djGPEcDzTgi2TDdcXvOw
  Persons	Bruce E. Sands

• Title	FDA Approves Mirikizumab (Omvoh) for Ulcerative Colitis; Eli Lilly and Company announced the FDA approval of mirikizumab (Omvoh) for moderately and severely active ulcerative colitis in adults on October 26, 2023.
  Media name/outlet	Consultant Live
  Country/Territory	United States
  Date	26/10/23
  Persons	Bruce E. Sands

• Title	FDA Approves Mirikizumab (Omvoh) for Ulcerative Colitis
  Media name/outlet	HCP Live
  Country/Territory	United States
  Date	26/10/23
  Persons	Bruce E. Sands